Compare BOSC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOSC | BOLD |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 36.5M |
| IPO Year | 2002 | 2024 |
| Metric | BOSC | BOLD |
|---|---|---|
| Price | $4.53 | $2.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 61.3K | ★ 2.2M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $0.96 |
| 52 Week High | $6.72 | $2.79 |
| Indicator | BOSC | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 83.19 |
| Support Level | $4.43 | $1.08 |
| Resistance Level | $4.93 | N/A |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 86.49 | 80.85 |
BOS Better Online Solutions Ltd is a provider of comprehensive solutions to enterprises, comprised of services, equipment, and custom-made automatic machines. The company manages its business in three reportable divisions: the Supply Chain Solutions Division, the RFID Division, and the Intelligent Robotics Division. The majority of revenue derives from Supply Chain Solutions, which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their component-supply needs. Its geographic areas are Israel, East Asia, India, America, Europe, and the rest of the world. Geographically company derives the majority of its revenue from Israel.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.